Intradialytic Hypotension Management in Dialysis Patients

Introduction to Levocarnitine Supplementation

The National Kidney Foundation and KDOQI guidelines recommend considering levocarnitine supplementation for dialysis patients with specific symptoms, failed standard therapies, and laboratory-confirmed carnitine deficiency 1

Candidates for levocarnitine supplementation include CKD patients on dialysis experiencing recurrent intradialytic hypotension who have not responded to standard therapies, with laboratory evidence of carnitine deficiency 1
Carnitine deficiency is confirmed by an acyl-to-free carnitine ratio >0.4 (normal ratio ≤0.25) and total serum carnitine <40 μmol/L, according to the American Journal of Kidney Diseases 1

The recommended regimens for managing intradialytic hypotension include intravenous administration of 20 mg/kg after each hemodialysis session or oral administration of 2-4g daily in divided doses, with a minimum duration of 12 weeks 1
Patients should be monitored for response to therapy, including tracking the frequency and severity of intradialytic hypotension episodes and reassessing carnitine levels periodically 1
Clinical symptoms, hemoglobin/hematocrit if treating anemia, and plasma carnitine levels (free and total) should be monitored, according to the American Journal of Kidney Diseases 2

Strong evidence supports the effectiveness of levocarnitine in reducing intradialytic hypotension, although studies often include small numbers of patients, which has compromised definitive evidence supporting regular supplementation 1
Side effects of levocarnitine supplementation may include gastrointestinal symptoms and "uremic breath" due to trimethylamine metabolites, particularly at higher doses (≥3g/day) 1, 2
High-dose L-carnitine therapy (≥3g/day) may cause gastrointestinal symptoms, including nausea, vomiting, abdominal cramps, and diarrhea, and "uremic breath" due to accumulation of trimethylamine metabolites, as stated by the American Journal of Kidney Diseases 2

Acetyl-L-carnitine may be considered in selected dialysis patients with documented carnitine deficiency for erythropoietin-resistant anemia, as suggested by the National Kidney Foundation 2
The recommended dosage for hemodialysis patients is 20 mg/kg IV after each hemodialysis session or 2-4g orally daily in divided doses, as reported by the American Journal of Kidney Diseases 2
The recommended dosage for neonates is 20-30 mg/kg/day, increasing to 50-100 mg/kg/day in severe cases, as stated by the American Academy of Pediatrics and other medical societies 3, 4
Standard dosing of L-carnitine for general supplementation is 2-5 mg/kg/day, aligning with physiological requirements, as recommended by the American College of Nutrition 4

ALCAR has several potential mechanisms, including facilitating fatty acid transport into mitochondria for β-oxidation, providing acetyl moiety for energy production and acetylcholine synthesis, modulating brain energy and phospholipid metabolism, reducing oxidative stress, and having neuroprotective effects in ischemia models 1, 2
The highest concentrations of L-carnitine are found in red meat, fish, poultry, and milk, with typical dietary intake in omnivores being 2-5 mg/kg/day (approximately 250 mg/day for a 70-kg adult) 4

Supplementation should be targeted to specific populations with demonstrated need rather than used routinely, as recommended by the American College of Nutrition and the National Kidney Foundation 4, 2
The National Kidney Foundation and KDOQI recommend considering a therapeutic trial of L-carnitine only when patients have specific symptoms, standard therapies have failed, and laboratory evidence confirms carnitine deficiency 1, 2